EDIT: Rasio kapitalisasi marang pendapatan Editas Medicine Inc

Simbol lan logo merek Editas (EDIT)

The price-to-sales chart for Editas Medicine, Inc. (EDIT), which attracts leading geneticists to advance CRISPR technologies, illustrates current dynamics where the 5.80 mark serves as a key metric. The company's foundation is built on genome editing patents, while future revenues will be based on therapies for ophthalmological and hematological pathologies following the completion of clinical trials.

Editas Medicine (EDIT): Multiplikator P/S saka 04.07.2022 nganti 17.11.2026

Rincian metrik lan analitis perusahaan Editas Medicine (EDIT)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis umum perusahaan:EDIT - Editas
Barang utama editasmedicine.com

Analyzing the market value of Editas Medicine, Inc. (EDIT) relative to its annual sales helps identify whether the asset is overbought or potentially undervalued, thereby mitigating the risk of capital freeze. Amidst a stable R&D backdrop for US biotechs, this revenue-based valuation of Editas Medicine, Inc. (EDIT) compares current market capitalization with actual earnings, demonstrating resource management efficiency during the period of post-crisis business recovery.

Karo sapa Editas Medicine, Inc. saingan

TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Rasio kapitalisasi marang pendapatan|10x Genomics Inc - Kapitalisasi marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rasio rega marang dodolan|Stoke Corp - Multiplikator P/S|BLFS (BioLife) - Rasio kapitalisasi marang pendapatan|wavelifesciences.com (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Prime Medicine Corp (PRME)|Multiplikator P/S TSHA|Multiplikator P/S uniQure N.V. (QURE)|Rasio rega marang pendapatan MeiraGTx Holdings plc MGTX|RGNX: Rasio kapitalisasi marang pendapatan|Solid Biosciences Inc - Multiplikator P/S|OCGN - Multiplikator P/S|PACB: Multiplikator P/S|BNTC - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Design Therapeutics, Inc.|RCKT: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Korro Bio, Inc. KRRO|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan